Active · per the CBE, 29 October 2026

UCB Fipar

BE0403198811

Rechtspersoon Public limited company 1 establishment

Researchdreef 60, 1070 Anderlecht

Active for

78 year, 11 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Busy address KBO

    10 other companies have their registered office at the same address; threshold 10.

  • Not on Peppol Peppol

    Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

UCB Fipar from Anderlecht, company number BE0403198811, closed financial year 2025 with a result of € 5.8 million after tax. Compared with financial year 2024, the result moved from € 407,938 to € 5.8 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 20, 2026.

What it is worth Growing

€ 38.6 million

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 5.8 million

▲ € 5.4 million vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 13,589

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 35.1 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2,100

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 50 days on average.

Key figures per fiscal year Download key figures (CSV)
2022202320242025Change 2024 → 2025
Profit after taxes € -293,393 € 482,158 € 407,938 € 5,842,379 ▲ € 5.4 million
Equity € 31,831,603 € 32,313,761 € 32,721,699 € 38,564,078 ▲ 18%
Total debts € 1,850 € 2,181 € 2,431 € 2,100 ▼ 14%
Cash - - - € 13,589
Retained profit € 28,331,603 € 28,813,761 € 29,221,699 € 35,064,078 ▲ 20%
Dividend € 80,000,000 € 0 € 0 € 0
Balance sheet total € 31,833,453 € 32,315,942 € 32,724,130 € 38,566,178 ▲ 18%

Key figures of UCB Fipar, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to UCB Fipar?

What happened at UCB Fipar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: profit of € 5.8 million (▲ € 5.4 million vs 2024). Source: NBB ↗
  • Jean-Christophe TELLIER stepped down as director. NBB
  • Sandrine DUFOUR stepped down as director. NBB
  • Loïc HAMEON stepped down as director. NBB
  • Denelle J. WAYNICK JOHNSON stepped down as director. NBB
  • Denelle J. WAYNICK JOHNSON became a director. NBB
  • Jean-Christophe TELLIER became a director. NBB
  • Sandrine DUFOUR became a director. NBB

In short

From € 293,393 loss in 2022 to € 5.8 million profit in 2025.

Paid € 5,457 in corporate taxes since 2022.

Best year ever: 2025, with € 5.8 million profit.

Paid out € 80 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

UCB BELGIUM SA 100%
UCB Fipar
EpilepsyGTx 42%
BlueHealth Innovation Fund 33.8%
Neurava, Inc. 7.9%
IMIDomics Inc. 6.8%
+10

The shares are held by UCB BELGIUM SA (100%). It owns 42% of EpilepsyGTx, 33.8% of BlueHealth Innovation Fund, 7.9% of Neurava, Inc., 6.8% of IMIDomics Inc., 3.7% of Bingli and 1.7% of UCB Pharma Lda itself.

Directors

According to the 2025 annual accounts

Jean-Christophe TELLIER

Director

Also active at: UCB PHARMA, UCB Ventures, UCB Ventures Belgium

since 2022 · until 2026

Sandrine DUFOUR

Director

Also active at: UCB Ventures Belgium

since 2022 · until 2026

Loïc HAMEON

Director

since 2022 · until 2026

Denelle J. WAYNICK JOHNSON

Director

Also active at: UCB BIOPHARMA, UCB Ventures, UCB Ventures Belgium

since 2023 · until 2026

Shareholders

UCB BELGIUM SA

100%

Participations

EpilepsyGTx

42%

BlueHealth Innovation Fund

33.8%

Neurava, Inc.

7.9%

IMIDomics Inc.

6.8%

Bingli

3.7%

UCB Pharma Lda

1.7%

EYSZ Inc

1%

UCB A.E. (Greece)

0.2%

UCB Pharma S.P.A. (Italy)

0.1%

UCB Pharma SA

0%

UCB Ventures Belgium

0%

UCB Ventures

0%

UCB De Mexico S.A. de C.V.

0%

UCB Biopharma S.A.

0%

Establishments

Establishment units

Physical locations of this company

Registered office

Researchdreef 60

1070 Anderlecht

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.

All companies at this address →

UCB Belgium same network

U C B

UCB PHARMA same network

€ 4.6 billion revenue · 2025

Fondation Emmanuel Janssen

UCB BIOPHARMA same network

€ 3.6 billion revenue · 2025

+5 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0403.198.811
VAT number
BE 0403.198.811
Registered office
Researchdreef 60, 1070 Anderlecht
Names & denominations
UCB Fipar
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
29 November 1947
Peppol
Not registered
View on CBE Public ↗ Annual accounts (NBB) ↗

Frequently asked questions

What is the address of UCB Fipar?
The registered office of UCB Fipar is located at Researchdreef 60, 1070 Anderlecht.
Is UCB Fipar still active?
Yes. According to the CBE (29 October 2026) UCB Fipar is active, legal situation “Normale toestand”, started on 29 November 1947.
Is UCB Fipar registered on Peppol?
No, UCB Fipar is currently not registered on the Peppol network.
What is the enterprise number of UCB Fipar?
The enterprise number of UCB Fipar is BE0403198811.
When was UCB Fipar founded?
UCB Fipar was founded on 29 November 1947.
Who owns UCB Fipar?
The shares are held by UCB BELGIUM SA (100%). It owns 42% of EpilepsyGTx, 33.8% of BlueHealth Innovation Fund, 7.9% of Neurava, Inc., 6.8% of IMIDomics Inc., 3.7% of Bingli and 1.7% of UCB Pharma Lda itself.